HomeCompareUNQL vs ABBV

UNQL vs ABBV: Dividend Comparison 2026

UNQL yields 51282.05% · ABBV yields 3.09%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 UNQL wins by $6.164318307325471e+23M in total portfolio value
10 years
UNQL
UNQL
● Live price
51282.05%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$6.164318307325471e+23M
Annual income
$614,076,267,853,163,140,000,000,000,000.00
Full UNQL calculator →
ABBV
AbbVie Inc.
● Live price
3.09%
Share price
$214.96
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$103.7K
Annual income
$25,324.79
Full ABBV calculator →

Portfolio growth — UNQL vs ABBV

📍 UNQL pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodUNQLABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, UNQL + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
UNQL pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

UNQL
Annual income on $10K today (after 15% tax)
$4,358,974.36/yr
After 10yr DRIP, annual income (after tax)
$521,964,827,675,188,650,000,000,000,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$262.96/yr
After 10yr DRIP, annual income (after tax)
$21,526.07/yr
At 15% tax rate, UNQL beats the other by $521,964,827,675,188,650,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of UNQL + ABBV for your $10,000?

UNQL: 50%ABBV: 50%
100% ABBV50/50100% UNQL
Portfolio after 10yr
$3.0821591536627355e+23M
Annual income
$307,038,133,926,581,570,000,000,000,000.00/yr
Blended yield
99.62%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

UNQL
No analyst data
Altman Z
3.6
Piotroski
4/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+19.2% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

UNQL buys
0
ABBV buys
7
PoliticianChamberTickerTypeAmountDate
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-18
Julia Letlow🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-08
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-11-13
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-31
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-30
Lisa McClain🏢 House$ABBV▲ Buy$1,001 - $15,0002025-10-30
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-08-14
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-11
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricUNQLABBV
Forward yield51282.05%3.09%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$6.164318307325471e+23M$103.7K
Annual income after 10y$614,076,267,853,163,140,000,000,000,000.00$25,324.79
Total dividends collected$6.16277212408334e+23M$62.2K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: UNQL vs ABBV ($10,000, DRIP)

YearUNQL PortfolioUNQL Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$5,138,905$5,128,205.13$11,555$434.96+$5.13MUNQL
2$2,468,429,435$2,462,930,806.71$13,485$635.47+$2468.42MUNQL
3$1,108,293,458,836$1,105,652,239,339.88$15,933$937.67+$1108293.44MUNQL
4$465,133,359,857,093$463,947,485,856,138.75$19,118$1,400.80+$465133359.84MUNQL
5$182,471,032,796,869,920$181,973,340,101,822,850.00$23,384$2,125.24+$182471032796.85MUNQL
6$66,912,846,333,441,070,000$66,717,602,328,348,430,000.00$29,290$3,286.81+$66912846333441.04MUNQL
7$22,936,650,503,380,730,000,000$22,865,053,757,803,946,000,000.00$37,776$5,205.38+$22936650503380732.00MUNQL
8$7,349,564,359,975,759,000,000,000$7,325,022,143,937,141,000,000,000.00$50,495$8,488.44+$7349564359975758848.00MUNQL
9$2,201,460,634,938,307,300,000,000,000$2,193,596,601,073,133,400,000,000,000.00$70,497$14,346.44+$2.2014606349383072e+21MUNQL
10$616,431,830,732,547,100,000,000,000,000$614,076,267,853,163,140,000,000,000,000.00$103,718$25,324.79+$6.164318307325471e+23MUNQL

UNQL vs ABBV: Complete Analysis 2026

UNQLStock

Unique Logistics International, Inc. operates as a logistics and freight forwarding company in the United States, China, Hong Kong, Taiwan, South East Asia, India Sub-continent, and internationally. It offers air and ocean freight, customs brokerage and compliance, warehouse and distribution, and order management services. The company is headquartered in Jamaica, New York.

Full UNQL Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this UNQL vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

UNQL vs SCHDUNQL vs JEPIUNQL vs OUNQL vs KOUNQL vs MAINUNQL vs JNJUNQL vs MRKUNQL vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.